PL2440230T3 - Schematy leczenia do leczenia choroby neurologicznej - Google Patents

Schematy leczenia do leczenia choroby neurologicznej

Info

Publication number
PL2440230T3
PL2440230T3 PL10786859T PL10786859T PL2440230T3 PL 2440230 T3 PL2440230 T3 PL 2440230T3 PL 10786859 T PL10786859 T PL 10786859T PL 10786859 T PL10786859 T PL 10786859T PL 2440230 T3 PL2440230 T3 PL 2440230T3
Authority
PL
Poland
Prior art keywords
treatment
neurological disease
regimes
treatment regimes
neurological
Prior art date
Application number
PL10786859T
Other languages
English (en)
Inventor
Michael Tymianski
Jonathan David Garman
Original Assignee
Nono Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nono Inc. filed Critical Nono Inc.
Publication of PL2440230T3 publication Critical patent/PL2440230T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL10786859T 2009-06-10 2010-06-10 Schematy leczenia do leczenia choroby neurologicznej PL2440230T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18598909P 2009-06-10 2009-06-10
EP10786859.8A EP2440230B1 (en) 2009-06-10 2010-06-10 Treatment regimes for treatment of neurological disease
PCT/US2010/038200 WO2010144721A2 (en) 2009-06-10 2010-06-10 Model systems and treatment regimes for treatment of neurological disease

Publications (1)

Publication Number Publication Date
PL2440230T3 true PL2440230T3 (pl) 2021-06-14

Family

ID=43309469

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10786859T PL2440230T3 (pl) 2009-06-10 2010-06-10 Schematy leczenia do leczenia choroby neurologicznej

Country Status (14)

Country Link
US (2) US8940699B2 (pl)
EP (2) EP3808366A1 (pl)
JP (2) JP6005514B2 (pl)
CN (1) CN102458441A (pl)
AU (1) AU2010258664B2 (pl)
BR (1) BRPI1010718A2 (pl)
CA (1) CA2765169C (pl)
DK (1) DK2440230T3 (pl)
ES (1) ES2847293T3 (pl)
HR (1) HRP20210112T1 (pl)
HU (1) HUE053131T2 (pl)
PL (1) PL2440230T3 (pl)
PT (1) PT2440230T (pl)
WO (1) WO2010144721A2 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
PT2440230T (pt) 2009-06-10 2021-02-03 Nono Inc Regimes de tratamento para tratamento de doenças neurológicas
ES2655112T3 (es) 2010-08-12 2018-02-16 Nono Inc. Tratamiento de una lesión penetrante en el cerebro
EP2723363B1 (en) 2011-06-24 2018-08-29 NoNO Inc. Combination therapy for ischemia
JP6279483B2 (ja) * 2011-12-13 2018-02-14 ノノ インコーポレイテッド くも膜下出血および虚血の治療法
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
AU2013204309A1 (en) * 2012-11-13 2014-05-29 Biodiem Limited Therapeutic Compounds and Uses Thereof
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
PL2925338T3 (pl) * 2012-11-28 2019-11-29 Nono Inc Liofilizowana formulacja TAT-NR2B9C
CN106661126B (zh) * 2014-05-28 2021-12-10 诺诺公司 TAT-NR2B9c的氯盐
JP2019522675A (ja) * 2016-04-27 2019-08-15 ▲拝▼西欧斯（北京）生物技▲術▼有限公司 興奮製神経毒性に関連した損傷の治療方法
KR102253900B1 (ko) * 2016-04-27 2021-05-18 바이오셀즈(베이징) 바이오테크 코., 엘티디. 흥분성 신경독성 관련 손상 치료용 펩타이드
WO2018103038A1 (zh) * 2016-12-08 2018-06-14 拜西欧斯（北京）生物技术有限公司 一种缀合物及其应用
CN110799547B (zh) * 2017-07-05 2023-02-28 拜西欧斯（北京）生物技术有限公司 用于治疗、改善或预防神经系统相关病症的化合物及其用途
BR112020000115A2 (pt) * 2017-07-05 2020-07-07 Biocells (Beijing) Biotech Co., Ltd. sais farmaceuticamente aceitáveis de polipeptídeos e uso dos mesmos
JP7073486B2 (ja) * 2017-09-30 2022-05-23 ▲拝▼西欧斯（北京）生物技▲術▼有限公司 興奮性神経毒性に関連した損傷の治療用ペプチド組成物
CN113150065B (zh) 2021-03-11 2022-07-08 武汉英纳氏药业有限公司 一种合成肽及其应用
CN113121641B (zh) 2021-03-11 2022-11-01 武汉英纳氏药业有限公司 一类多功能多肽及其在医药领域的应用
CN113735938B (zh) 2021-07-30 2024-11-08 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用
CN114642402A (zh) * 2022-03-07 2022-06-21 翰博瑞强(上海)医药科技有限公司 一种用于预测药物对心脏毒性影响的方法及心电图设备
CN114469084B (zh) * 2022-04-02 2022-06-24 剑博微电子(深圳)有限公司 一种基于高精度adc的血氧监测系统

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060148711A1 (en) 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
GB0025473D0 (en) 2000-10-17 2000-11-29 Pfizer Ltd Pharmaceutical combinations
WO2004045535A2 (en) * 2002-11-14 2004-06-03 Arbor Vita Corporation Molecular interactions in neurons
EP1601380A1 (en) 2003-02-13 2005-12-07 Licentia OY Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
EP1622639B1 (de) 2003-05-02 2013-01-16 Lundbeck, H., A/S Intravenöse injektion nicht-neurotoxischer plasminogen-aktivatoren zur behandlung von schlaganfall
WO2008008348A2 (en) 2006-07-11 2008-01-17 Arbor Vita Corporation Method and compositions for treating stroke with fever
EP1884521A1 (en) * 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
DK2120987T3 (en) 2007-03-02 2014-02-24 Nono Inc Treatment of stroke and other diseases without inhibiting N-type calcium channels
WO2009006611A1 (en) 2007-07-03 2009-01-08 Arbor Vita Corporation Small molecule inhibitors of pdz interactions
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
WO2010004003A2 (en) 2008-07-09 2010-01-14 University Of Copenhagen Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction
PT2440230T (pt) 2009-06-10 2021-02-03 Nono Inc Regimes de tratamento para tratamento de doenças neurológicas
EP2723363B1 (en) 2011-06-24 2018-08-29 NoNO Inc. Combination therapy for ischemia
JP6279483B2 (ja) 2011-12-13 2018-02-14 ノノ インコーポレイテッド くも膜下出血および虚血の治療法
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia

Also Published As

Publication number Publication date
AU2010258664A1 (en) 2012-01-12
CA2765169A1 (en) 2010-12-16
AU2010258664B2 (en) 2015-05-28
PT2440230T (pt) 2021-02-03
EP2440230A4 (en) 2014-05-28
US20120269733A1 (en) 2012-10-25
US20150202253A1 (en) 2015-07-23
US8940699B2 (en) 2015-01-27
JP6005514B2 (ja) 2016-10-12
EP2440230B1 (en) 2020-11-11
CN102458441A (zh) 2012-05-16
US9610323B2 (en) 2017-04-04
DK2440230T3 (da) 2021-01-18
HUE053131T2 (hu) 2021-06-28
JP2016041731A (ja) 2016-03-31
WO2010144721A3 (en) 2011-04-21
ES2847293T3 (es) 2021-08-02
HRP20210112T1 (hr) 2021-04-16
EP2440230A2 (en) 2012-04-18
BRPI1010718A2 (pt) 2016-03-15
JP2012530057A (ja) 2012-11-29
JP6220371B2 (ja) 2017-10-25
CA2765169C (en) 2019-06-18
WO2010144721A2 (en) 2010-12-16
EP3808366A1 (en) 2021-04-21

Similar Documents

Publication Publication Date Title
PL2440230T3 (pl) Schematy leczenia do leczenia choroby neurologicznej
IL217777A0 (en) Methods for treatment of pain
IL217901A0 (en) Treatment of bdnf-related disorders using laquninimod
IL219073A (en) A drug combination for cancer treatment
EP2409634A4 (en) ENDOSCOPE OF TREATMENT
IL211857A (en) Neurological Treatment System
IL215767A0 (en) Methods of treatment for solid tumors
GB0908193D0 (en) Treatment of disease state
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
ZA201109278B (en) Method for treatment of diseases
PL2477656T3 (pl) Leczenie stanów neurologicznych
GB0914839D0 (en) Treatment of oil
ZA201202379B (en) Antagonists of dsgs2 for treatment of cancer
GB0908666D0 (en) Treatment of proteostatic disease
GB0819543D0 (en) Treatment of proteostatic disease
GB0817859D0 (en) Treatment of proteostatic disease
HU0900722D0 (en) Compounds for the treatment of neurological disorders
TWM390783U (en) Improved structure of push bed for medical treatment
HUP0900504A2 (en) Cream for treatment of skin-irritation
GB0913427D0 (en) Compounds for treatment of imflammation
HK1173678A (en) Treatment of neurological conditions
GB0911418D0 (en) Treatment of degenerative disc disease
GB0906179D0 (en) Treatment of proteostatic desease